About: Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
Creator	Wang, Fan Lother, Sylvain Abassi, Mahsa Boulware, David Lee, Todd Lofgren, Sarah Mitjà, Oriol Okafor, Elizabeth Pastick, Katelyn Pullen, Matthew Rajasingham, Radha Schwartz, Ilan Skipper, Caleb Mcdonald, Emily Nicol, Melanie Kelly, Lauren Letang, Emili
Source	Medline; PMC
abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.
has issue date	2020-04-15(xsd:dateTime)
bibo:doi	10.1093/ofid/ofaa130
bibo:pmid	32363212
has license	cc-by-nc-nd
sha1sum (hex)	9c230522b6276fc65f397c9aed635453d8148253
schema:url	https://doi.org/10.1093/ofid/ofaa130
resource representing a document's title	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
has PubMed Central identifier	PMC7184359
has PubMed identifier	32363212
schema:publication	Open Forum Infect Dis
resource representing a document's body	covid:9c230522b6276fc65f397c9aed635453d8148253#body_text
is schema:about of	named entity 'QTc prolongation' named entity 'potential' named entity 'Hydroxychloroquine' named entity 'perform' named entity 'therapeutic' named entity 'Here' named entity 'causing' named entity 'Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'HAVE' named entity 'VIRAL INFECTION' named entity 'CONCERN' named entity 'body' named entity 'clinical trials' named entity 'evidence' named entity 'growing' named entity 'limitations' named entity 'rapid' named entity 'Hydroxychloroquine' named entity 'case series' named entity 'scientific data' named entity 'cardiac arrhythmias' named entity 'hydroxychloroquine' named entity 'chloroquine' named entity 'Hydroxychloroquine' named entity 'Infectious Diseases' named entity 'COVID-19' named entity 'Hydroxychloroquine' named entity 'intestinal absorption' named entity 'clinical outcomes' named entity 'Standard of care' named entity 'infection' named entity 'peak plasma concentration' named entity '95% confidence interval' named entity 'hydroxychloroquine' named entity 'health systems' named entity 'amebiasis' named entity 'hydroxychloroquine' named entity 'national treatment' named entity 'randomized trials' named entity 'chloroquine' named entity 'hydroxychloroquine' named entity 'arrhythmia' named entity 'hydroxychloroquine' named entity 'electrolyte abnormalities' named entity 'chest CT' named entity 'countries and territories' named entity 'randomized clinical trials' named entity 'selective serotonin reuptake inhibitors' named entity 'arrhythmias' named entity 'cough' named entity 'evidence base' named entity 'viral infection' named entity 'treatment of patients' named entity 'virion' named entity 'tricyclic antidepressants' named entity 'prospective cohort' named entity 'SARS-CoV' named entity 'SARS-CoV-2' named entity 'systemic lupus erythematosus' named entity 'approved drug' named entity 'physiologically based pharmacokinetic' named entity 'nasopharyngeal' named entity 'chloroquine' named entity 'statistical difference' named entity 'arrhythmias'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software